The October update to the AHFS Drug Information/Essentials database was published today. Highlights from this month’s update include:

New AHFS/Essentials Monographs

Alectinib (Alecensa^®)
Antihemophilic Factor (Recombinant), Porcine Sequence (Obizur^®)
Antihemophilic Factor (recombinant), Fc Fusion Protein (Eloctate^®)
Asfotase Alfa (Strensiq^®)
Atezolizumab (Tecentriq^®)
Avanafil (Stendra^®)
Brexpiprazole (Rexulti^®)
Brivaracetam (Briviact^®)
Cariprazine (Vraylar^®)
Cholic Acid (Cholbam^®)
Coagulation Factor IX (Recombinant, Human) (Idelvion^®)
Coagulation Factor X Human (Coagadex^®)
Cobicistat (Tybost^®, Evotaz^®, Prezcobix^®, Stribild^®)
Daclizumab (Zinbryta^®)
Daratumumab (Darzalex^®)
Defibrotide Sodium  (Defitelio^®)
Deoxycholic Acid (Kybella^®)
Dichlorphenamide (Keveyis^®)
Eliglustat (Cerdelga^®)
Elotuzumab (Empliciti^®)
Elvitegravir (Vitekta^®)
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (Genvoya^®)
Eteplirsen (Exondys 51^®)
Idarucizumab (Praxbind^®)
Insulin Degludec (Tresiba^®)
Ivabradine Hydrochloride (Corlanor^®)
Ixazomib (Ninlaro^®)
Ixekizumab (Taltz^®)
Lesinurad (Zurampic^®)
Lifitegrast (Xiidra^®)
Lixisenatide (Adlyxin^®)
Lumacaftor and Ivacaftor (Orkambi^®)
Mepolizumab (Nucala^®)
Metreleptin (Myalept^®)
Necitumumab (Portrazza^®)
Netupitant and Palonosetron (Akynzeo^®)
Obeticholic Acid (Ocaliva^®)
Obiltoxaximab (Anthim^®)
Osimertinib (Tagrisso^®)
Palbociclib (Ibrance^®)
Patiromer (Veltassa^®)
Pimavanserin (Nuplazid^®)
Raxibacumab
Reslizumab (Cinqair^®)
Rolapitant (Varubi^®)
Sacubitril and Valsartan (Entresto (with valsartan)^®)
Sebelipase Alfa (Kanuma^®)
Selexipag (Uptravi^®)
Sonidegib (Odomzo^®)
Sugammadex (Bridion^®)
Trabectedin (Yondelis^®)
Trifluridine and Tipiracil (Lonsurf^®)
Venetoclax (Venclexta^®)